30 closest matches · ranked by relevance
Breast Cancer · Invasive Breast Cancer
Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…
Breast Cancer
Primary: Percentage of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Specimens Using Immunohistochemistry (IHC) and Silver In-Situ…
Breast Cancer
Primary: Pathological Response for Basal Group 2 — 16; 14; 5; 11 Participants
Malignant Neoplasm of Female Breast
Primary: Overall Response Rate — 25; 21 Participants
Gastric Cancer, Gastroesophageal Junction Cancer
Primary: Simple Kappa Coefficient of Human Epidermal Growth Factor Receptor 2 (HER-2) Status Between Local and Centralized Laboratory Assessments — 0.69 kappa coefficient…
Breast Cancer
Primary: Percentage of Participants With Immunohistochemical (IHC) Evaluation Between Site A and Others (Sites B, C, D and E) — 16.7; 12.5; 0.0; 8.3 percentage of participants
Breast Cancer
Primary: Overall Disease Response Rate — 0; 0; 1; 1 Participants
Breast Cancer
Primary: Objective Response Rate (ORR) by Investigator Assessment — 12.3 percentage of participants
Locally Recurrent · Metastatic Breast Cancer ( HER2 Negative)
Primary: Objective Response Rate (ORR) — 28.6 Percentage of participants
Breast Neoplasm
Primary: Best Overall Response (BOR) — 20.0; 10.3 percentage of participants — p=0.1109
Breast Neoplasms
Primary: Objective Response (OR) — 0 Participants with OR
Breast Neoplasms · Neoplasms
Primary: 16-week Progression Free Survival — 58.2; 77.8 percentage of participants
Breast Cancer
Primary: Pathologic Complete Response Rate After Preoperative Therapy With Cisplatin and Bevacizumab in ER-, PR-, Human Epidermal Growth Factor Receptor 2 (HER2) -Negative Early…
Breast Cancer
Primary: Change in Ki-67 in Breast Tissue of High-Risk Women
Neoplasms, Breast
Primary: Overall Tumor Response — 1; 8; 18; 29 participants
Breast Cancer
Primary: Pathological Complete Response Rates at Surgery — 16; 2 participants
Breast Cancer
Primary: The Residual Cancer Burden Grade III (RCB-III). — 23; 37; 14; 6 Participants
Breast Cancer
Primary: Complete Response Rate — 2; 8 Participants
Breast Cancer
Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months
Breast Cancer
Primary: Invasive Disease-free Survival (DFS) — 42; 47 Participants
Advanced Breast Cancer · Breast Cancer
Primary: Progression Free Survival — 4.53; 6.83 months — p=0.231
Breast Cancer
Primary: Objective Response Rate Per Composite Response Criteria — 7.5; 48.6; 33.3 percent of participants
Triple Negative Locally Advanced Non-resectable Breast Cancer · Metastatic Breast Cancer
Primary: Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST]) — 30.0; 35.9 percentage of participants
Breast Cancer
Primary: Pathologic Complete Response in Breast and Axillary Lymph Nodes. — 16; 14; 21; 5 Participants
Metastatic Breast Cancer
Primary: Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) — 3; 3; 15; 15 Participants
Metastatic Beast Cancer
Primary: Progression-free Survival (PFS) Rate at 3 Months — 50.1 percent of participants
Breast Cancer
Primary: Progression Free Survival (PFS) at the Time of Primary Results — 8.97; 11.30; 9.13; 13.63 Months — p=0.0010
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Breast Cancer · Carcinoma of the Breast
Primary: 3-year Disease Free Survival (DFS) Rate — 0.987 proportion of participant
Breast Cancer
Primary: Number of Participants With a Pathological Complete Response — 21; 24; 99; 89 participants